scispace - formally typeset
S

Shamsah B. Sonawalla

Researcher at Harvard University

Publications -  34
Citations -  1444

Shamsah B. Sonawalla is an academic researcher from Harvard University. The author has contributed to research in topics: Major depressive disorder & Depression (differential diagnoses). The author has an hindex of 20, co-authored 34 publications receiving 1385 citations.

Papers
More filters
Journal ArticleDOI

A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction.

TL;DR: Macha root may alleviate SSRI‐induced sexual dysfunction, and there may be a dose‐related effect, and Maca may also have a beneficial effect on libido.
Journal ArticleDOI

Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine

TL;DR: It is found that there are no significant differences in efficacy among these three treatment strategies among patients who had failed to respond adequately to 8 weeks of treatment with fluoxetine 20 mg/day, although the high-fluoxettine group was associated with nonsignificantly higher response rates in both partial responders and nonresponders.
Journal ArticleDOI

Comparing anxiety disorders and anxiety-related traits in bipolar disorder and unipolar depression.

TL;DR: This study supports prior research suggesting a specific panic disorder-bipolar disorder connection and suggests GAD may also be differentially associated with BPD, and suggests anxiety sensitivity and neuroticism did not differ by mood disorder type.
Journal ArticleDOI

Personality disorders and depression.

TL;DR: In this paper, the authors assessed personality disorders (PDs) among depressed outpatients by clinical interview before and after antidepressant treatment with fluoxetine to assess the degree of stability of PD diagnoses and determine whether changes in PD diagnoses across treatment are related to an improvement in depressive symptoms.
Journal ArticleDOI

A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder.

TL;DR: EPA demonstrated an advantage over placebo that did not reach statistical significance, possibly due to the small sample and low completer rates, which were the major study limitations.